Maple Rock Capital Partners Inc. lessened its holdings in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,171,053 shares of the company's stock after selling 446,495 shares during the quarter. Bausch + Lomb makes up about 1.7% of Maple Rock Capital Partners Inc.'s investment portfolio, making the stock its 9th biggest position. Maple Rock Capital Partners Inc. owned 0.90% of Bausch + Lomb worth $57,269,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC purchased a new stake in Bausch + Lomb during the third quarter valued at about $5,797,000. Raymond James Financial Inc. acquired a new stake in Bausch + Lomb during the 4th quarter worth approximately $2,844,000. State Street Corp lifted its position in Bausch + Lomb by 5.6% during the third quarter. State Street Corp now owns 28,450 shares of the company's stock valued at $549,000 after buying an additional 1,510 shares in the last quarter. Ellsworth Advisors LLC acquired a new stake in shares of Bausch + Lomb in the fourth quarter worth $665,000. Finally, Renaissance Technologies LLC purchased a new stake in Bausch + Lomb during the 4th quarter worth $372,000. Hedge funds and other institutional investors own 11.07% of the company's stock.
Bausch + Lomb Price Performance
Shares of NYSE BLCO traded up $0.40 during mid-day trading on Wednesday, reaching $11.30. The company had a trading volume of 231,009 shares, compared to its average volume of 649,458. Bausch + Lomb Co. has a 1-year low of $10.45 and a 1-year high of $21.69. The stock has a market cap of $3.99 billion, a PE ratio of -12.37, a P/E/G ratio of 0.85 and a beta of 0.58. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average price of $13.72 and a two-hundred day moving average price of $16.75.
Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm had revenue of $1.15 billion during the quarter, compared to analysts' expectations of $1.15 billion. During the same quarter last year, the company posted $0.07 EPS. The firm's revenue was up 3.5% compared to the same quarter last year. On average, equities analysts anticipate that Bausch + Lomb Co. will post 0.74 earnings per share for the current year.
Analyst Ratings Changes
BLCO has been the topic of several recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Wells Fargo & Company lowered their price target on shares of Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. Morgan Stanley cut their price objective on shares of Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating on the stock in a report on Tuesday. Royal Bank of Canada lowered their target price on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, April 4th. Finally, Citigroup cut their price target on Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $15.50.
Check Out Our Latest Stock Analysis on BLCO
Bausch + Lomb Profile
(
Free Report)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Further Reading
Before you consider Bausch + Lomb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.
While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
